ClinicalTrials.gg
CompletedNCT06289166Updated Jan 22, 2025

Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with Inhibitor

A Phase 2 interventional study of STSP-0601 for Injection in Hemophilia, sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd. Completed at 20 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-01-22.

Sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 93 studies in Hemophilia A with a site in China — 28 open to participants now, 39 under way, 19 of them phase 3. Hemophilia A · China.

Enrollment
57th of 80
25 · median 54
Started
2024
with 9 others
Phase 2
4 of 93
none open now
Registered
73rd of 93
by date
Lead sponsor
4 of 93
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Among the 93 studies in Hemophilia A with a site in China, this one is the 57th largest by enrollment of the 80 interventional ones that give a count, is one of 10 that started in 2024, is one of 4 in phase 2, and was the 73rd registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

28 of the 93 studies in Hemophilia A with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies in Hemophilia A with a site in China, or all of them as a file.
02

Study summary

This study will assess the safety and efficacy of multiple-dose of STSP-0601 for the treatment of bleeding episodes in hemophilia A or B patients with inhibitor.

03

Conditions studied

  • Hemophilia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 ≤age≤70 years of age,male.
  2. Hemophilia A or B patients. (No less than 3 patients with hemophilia B)
  3. Peak historical inhibitor titer ≥ 5 BU and apositive inhibitor test when enrolled.
  4. Establish proper venous access.
  5. There were at least 3 bleeding events that requiring treatment occurred in the past 6 months before screening (Only applicable to the on-demand treatment stage).
  6. Agree to use adequate to avoid pregnancy. Agree not to donate sperm or eggs.
  7. Provide signed .

Exclusion criteria

Exclusion Criteria:

  1. Have any coagulation disorder other than hemophilia.
  2. Plan to receive prophylactic treatment of coagulation factor during the trail.
  3. Patients plan to receive Emicizumab during the trial.
  4. Patients received anticoagulant or antifibrinolytic therapy 7 days before enrollment or plan to receive these drugs during the trial.Patients received anticoagulation therapy (such as coagulation factor replacement therapy, prothrombin complex, plasma, etc.) 7 days before enrollment.
  5. Have a history of arterial and/or venous thrombotic events.
  6. \<100×109/L.
  7. \<90g/L.
  8. Severe liver or kidney disease.
  9. Severe bleeding event occurred within 4 weeks before enrollment.
  10. Accepted major operation or blood transfusion within 4 weeks before enrollment.
  11. Have a known allergy to STSP-0601.
  12. Pregnant, lactating, or blood pregnancy test positive female subjects
  13. Participate in other clinical research within 4 weeks before enrollment(except for participating in prothrombin complex, FVII, FVIIa, FVIII, FIX trails).
  14. Within 1 day prior to enrollment, FVII, FVIIa, tranexamic acid, and aminocaproic acid were used. Within 3 days prior to enrollment, prothrombin complex, FVIII, and FIX were used. Within 4 weeks prior to enrollment, treatment with amisulumab was received.
  15. Patients not suitable for the trail according to the judgment of the investigators.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Consecutive doses of STSP-0601

    Drug: STSP-0601 for Injection

Interventions

  • A Multiple-dose Design to Evaluate the Safety, Tolerability and Efficacy of STSP-0601 for Injection in hemophilia A or B patients with inhibitor.

06

What researchers measure

Primary outcomes

  1. Proportion of successfully treated bleeding episodes

    Time frame: 12 hours after first administration of study drug

Secondary outcomes

  1. Proportion of successfully treated first bleeding episodes

    Time frame: 12 hours after first administration of study drug

  2. Proportion of successfully treated bleeding episodes

    Time frame: 8 hours after first administration of study drug

  3. Excellent + good rate of treated bleeding episodes

    Excellent: Pain and Symptoms of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal haemorrhage) had fully eased. No additional infusion of study drug was required. Good: Symptoms of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal haemorrhage) had largely eased , but had not completely disappeared. No additional infusion of study drug was required.

    Time frame: 12 hours after first administration of study drug

  4. Excellent + good rate of treated bleeding episodes

    Excellent: Pain and Symptoms of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal haemorrhage) had fully eased. No additional infusion of study drug was required. Good: Symptoms of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal haemorrhage) had largely eased , but had not completely disappeared. No additional infusion of study drug was required.

    Time frame: 8 hours after first administration of study drug

  5. Number of doses required for effective hemostasis

    Time frame: 12 hours after first administration of study drug

  6. Proportion of bleeding episodes received salvage treatment

    Time frame: 24 hours after first administration of study drug

  7. Time to complete/significant remission from first dose

    Time frame: 72 hours after last administration of study drug

  8. Time to complete/significant remission from haematogenesis

    Time frame: 72 hours after last administration of study drug

  9. Proportion of successfully treated Target joint bleeding episodes

    Time frame: 12 hours after first administration of study drug

07

Study locations

20 sites
  • Anhui Provincial Hospital
    Hefei, Anhui 230000, China
  • The Second Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing 400000, China
  • Fujian Medical University Affiliated Union Medical College Hospital
    Fuzhou, Fujian 350005, China
  • Lanzhou University First Hospital
    Lanzhou, Gansu 730000, China
  • Southern Medical University Southern Hospital
    Guangzhou, Guangdong 510000, China
  • Shenzhen Second People's Hospital
    Shenzhen, Guangdong 518000, China
  • Guizhou Medical University Affiliated Hospital
    Guiyang, Guizhou 550000, China
  • Harbin First Hospital Hematology Tumor Research Center
    Harbin, Heilongjiang 150000, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
  • Xiangya Hospital of Central South University
    Changsha, Hunan 410000, China
  • Nanjing University School of Medicine Affiliated Gulou Hospital
    Nanjing, Jiangsu 210000, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330038, China
  • The first hospital of Jilin University
    Changchun, Jilin 130000, China
  • Shengjing Hospital Affiliated to China Medical University
    Shenyang, Liaoning 110000, China
  • Affiliated Hospital of Qingdao University
    Qingdao, Shandong 266000, China
  • Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai 200000, China
  • Xi'an Central Hospital
    Xi'an, Shanxi 710000, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610000, China
  • Hospital of Hematology, Chinese Academy of Medical Sciences
    Tianjin, Tianjin 300020, China
  • The Second Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan 650000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Oct 2024, 6 months.

Of 18 phase 2 interventional studies under Hemophilia A, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 20. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2024
First posted
Mar 1, 2024
StartActual
Mar 18, 2024
Primary completionActual
Oct 17, 2024
CompletionActual
Oct 17, 2024
Last update
Jan 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06289166
Responsible party
Sponsor
First posted
Mar 1, 2024
Start date
Mar 18, 2024
Primary completion
Oct 17, 2024
Completion
Oct 17, 2024
Last update
Jan 22, 2025

Study contacts

Lei Zhang, Ph.D
principal investigator · Hospital of Hematology, Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: STSP-0601

Start the discussion